|
Gene: ZNF665 |
Gene summary for ZNF665 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZNF665 | Gene ID | 79788 |
Gene name | zinc finger protein 665 | |
Gene Alias | ZFP160L | |
Cytomap | 19q13.42 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9H7R5 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79788 | ZNF665 | HCC1 | Human | Liver | HCC | 6.03e-10 | 1.35e+00 | 0.5336 |
79788 | ZNF665 | HCC2 | Human | Liver | HCC | 6.34e-23 | 1.60e+00 | 0.5341 |
79788 | ZNF665 | HCC5 | Human | Liver | HCC | 1.59e-13 | 1.67e+00 | 0.4932 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
ZNF665 | CHO | Liver | Cirrhotic | MBD5,MAPK10,GALNT5, etc. | 3.98e-01 |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF665 | SNV | Missense_Mutation | c.1449N>C | p.Glu483Asp | p.E483D | Q9H7R5 | protein_coding | deleterious(0.02) | benign(0.017) | TCGA-A2-A04Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
ZNF665 | SNV | Missense_Mutation | novel | c.1781G>A | p.Gly594Glu | p.G594E | Q9H7R5 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
ZNF665 | SNV | Missense_Mutation | c.1627A>C | p.Lys543Gln | p.K543Q | Q9H7R5 | protein_coding | deleterious(0.04) | benign(0.43) | TCGA-E2-A14R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD | |
ZNF665 | SNV | Missense_Mutation | rs866466787 | c.1429C>T | p.Arg477Trp | p.R477W | Q9H7R5 | protein_coding | tolerated(0.06) | possibly_damaging(0.742) | TCGA-E2-A1AZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
ZNF665 | insertion | Frame_Shift_Ins | novel | c.1144_1145insGTCTCGAGTTCGAGACCAGGCTGGCCAACACGGTGAAA | p.Ala382GlyfsTer21 | p.A382Gfs*21 | Q9H7R5 | protein_coding | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
ZNF665 | insertion | Nonsense_Mutation | novel | c.1590_1591insGCATGCTGAGACTGTTACTCCTGGACCACAA | p.Ile531AlafsTer3 | p.I531Afs*3 | Q9H7R5 | protein_coding | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
ZNF665 | SNV | Missense_Mutation | c.502G>C | p.Glu168Gln | p.E168Q | Q9H7R5 | protein_coding | tolerated(0.07) | benign(0.36) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ZNF665 | SNV | Missense_Mutation | rs754537311 | c.1094N>A | p.Arg365Gln | p.R365Q | Q9H7R5 | protein_coding | tolerated(1) | benign(0.014) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
ZNF665 | SNV | Missense_Mutation | c.1300G>A | p.Glu434Lys | p.E434K | Q9H7R5 | protein_coding | tolerated(0.08) | possibly_damaging(0.806) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR | |
ZNF665 | SNV | Missense_Mutation | novel | c.857G>C | p.Gly286Ala | p.G286A | Q9H7R5 | protein_coding | deleterious(0.03) | possibly_damaging(0.733) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |